serpin family B member 2Genealiases: HsT1201 · PAI · PAI-2 · PAI2 · PLANH2
Q-omics provides the consensus-scored SERPINB2 profile across patient tissues and cancer cell-line models. SERPINB2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SERPINB2 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, SERPINB2 RNA expression shows 12,732 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where SERPINB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINB2 survival associations across molecular data types. SERPINB2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINB2 RNA expression–survival associations across cancer types. High SERPINB2 expression shows unfavorable associations in KIRC, UVM, BLCA, LIHC, ACC and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SERPINB2 RNA expression.
This table summarizes SERPINB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SERPINB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINB2 shows lower tumor expression in HNSC and KICH and higher tumor expression in LUSC, COAD, THCA and READ. The LUSC box plot shows higher SERPINB2 RNA expression in tumor versus normal tissue (log2 FC = +2.708, t-test p < 0.001).
This table shows molecular features associated with SERPINB2 in patient tissues and cancer cell lines. In patient samples, SERPINB2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
